PAM
RLMD icon

Panagora Asset Management’s Relmada Therapeutics RLMD Stock Holding History

Panagora Asset Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-195
Closed -$6K – 2910
2020
Q4 		$6K Hold
195
– – ﹤0.01% 2427
2020
Q3 		$7K Buy
+195
New +$7.54K ﹤0.01% 2387

Other funds holding RLMD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Panagora Asset Management's RLMD Position: Q1 2021 in Review

Panagora Asset Management sold out of Relmada Therapeutics (RLMD) in Q1 2021, closing a stake of 195 shares — an estimated $6K sold.

Panagora Asset Management first reported a position in RLMD in Q3 2020 and held it in 2 quarters. The position peaked at $7K in Q3 2020. 82 funds tracked by Wall St. Rank hold RLMD as of Q1 2021.

  • Panagora Asset Management reported no remaining Relmada Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Panagora Asset Management sold 195 Relmada Therapeutics shares in Q1 2021, an estimated $6K.
  • Panagora Asset Management first reported a position in Relmada Therapeutics in Q3 2020 and held it in 2 quarters.
  • Panagora Asset Management's Relmada Therapeutics position peaked at $7K in Q3 2020.
  • 82 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2021.

Based on Panagora Asset Management's 13F filing for Q1 2021, filed 12 May 2021.